FBW7 wild‐type and R465C‐mutant tumor samples were collected from CRC patients; the clinical records showed that the patient harboring the FBW7 R465C mutation exhibited disease progression after irinotecan‐based chemotherapy (Table S3), suggesting this mutation may also induce irinotecan resistance. Here, FBXW7 is linked to neoplasm.